Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: aggressive investor who wrote (48)	9/27/1997 7:20:00 PM
From: Pseudo Biologist	Respond to of 666

Thanks Steve, I'll keep my eyes peeled. The run from the 9's to the 13-14 range has been quick, smooth and with relatively high volume. Thus far, it just looks as moving in sympathy with the whole biotech sector. Not clear what role the purchase of Coulter by Beckman is playing here at all. In any case, if one accepts IDEC's present valuation and further assumes that is mostly due to C2B8 and related NHL products, CLTR is still pretty cheap even after considering that it may be a year or so behind IDEC. Of course, this assumes Bexxar works; a strong probability but not a certainty before unveiling of the phase III. PB

To: aggressive investor who wrote (48)	9/29/1997 12:48:00 PM
From: Pseudo Biologist	Respond to of 666

Way to go Steve, On 9/27 you wrote re. a possible secondary offering <<It is just a something briefly overheard in the office at this point. Nothing cirtain. I thought someone else here would know and could tell me more ..>> Coulter indeed announced today a follow-on offering of 2 million shares (plus 300K for green shoe). It looks as if one should pay attention to whatever is said in "the office." There was also an 8-K filed today; I have not looked at it in detail but it seems to deal with their manufacturing agreement with Lonza (sp?). PB

To: aggressive investor who wrote (48)	8/22/1998 12:21:00 PM
From: Bioscoop	Respond to of 666

It is very obvious. They have misled investors about their data, they risk getting delayed by the FDA, and since their stock is so high why not raise more money because the clinical trial costs are rising exponentially. I hear they pay the highest per patient to provide an incentive to the doctor. And what if the partnership deal requires giving up the U.S. market, they are left with no pipeline. And if IDEC Y2B8 takes a large share of the market they are sunk, so why not raise money now before the reality sinks in.